Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: Submissions Galore, And Still More 'Breakthroughs'

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber

Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.

Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK

The latest drug development news and highlights from our US FDA Performance Tracker.

Ground Hog Day For Merck: FDA Again Cancels Sugammadex Advisory Committee Review

FDA is conducting additional inspections of the site of a hypersensitivity study the agency requested in 2008; concerns about the study derailed a committee review in 2013.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel